Wealth Enhancement Advisory Services LLC Purchases 1,095 Shares of Jazz Pharmaceuticals PLC $JAZZ

Wealth Enhancement Advisory Services LLC boosted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 25.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,429 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,095 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Jazz Pharmaceuticals were worth $594,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new position in shares of Jazz Pharmaceuticals during the first quarter worth $62,362,000. Fuller & Thaler Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals by 41.7% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after acquiring an additional 391,660 shares in the last quarter. Perpetual Ltd increased its position in shares of Jazz Pharmaceuticals by 60.2% during the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company’s stock worth $118,212,000 after acquiring an additional 357,784 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Jazz Pharmaceuticals by 14.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after acquiring an additional 293,360 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Jazz Pharmaceuticals by 147.7% during the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after purchasing an additional 209,667 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 11,500 shares of company stock valued at $1,525,280 over the last quarter. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $139.48 on Friday. The firm has a 50 day moving average of $123.75 and a 200 day moving average of $115.66. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $8.46 billion, a price-to-earnings ratio of -20.73, a price-to-earnings-growth ratio of 8.65 and a beta of 0.28. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the prior year, the firm earned $5.30 EPS. Jazz Pharmaceuticals’s revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a “buy” rating and a $152.00 target price on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Saturday, September 27th. The Goldman Sachs Group raised their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Finally, Morgan Stanley increased their target price on shares of Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. Fourteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $178.93.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.